NCT00559091View on ClinicalTrials.gov

A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Acute Myelocytic Leukemia
Interventions
DRUG

ribavirin

Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.

Trial Locations (3)

L8N 3Z5

McMaster Hospital, Hamilton

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

H4T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Jewish General Hospital

OTHER

NCT00559091 - A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia | Biotech Hunter | Biotech Hunter